Literature DB >> 30556258

Peripheral nervous system involvement in lymphomas.

Chiara Briani1, Andrea Visentin2, Marta Campagnolo1, Alessandro Salvalaggio1, Sergio Ferrari3, Tiziana Cavallaro3, Renzo Manara4, Roberto Gasparotti5, Francesco Piazza2.   

Abstract

The peripheral nervous system may be involved at any stage in the course of lymphoproliferative diseases. The different underlying mechanisms include neurotoxicity secondary to chemotherapy, direct nerve infiltration (neurolymphomatosis), infections, immune-mediated, paraneoplastic or metabolic processes and nutritional deficiencies. Accordingly, the clinical features are heterogeneous and depend on the localization of the damage (ganglia, roots, plexi, and peripheral nerves) and on the involved structures (myelin, axon, and cell body). Some clinical findings, such a focal or diffuse involvement, symmetric or asymmetric pattern, presence of pain may point to the correct diagnosis. Besides a thorough medical history and neurological examination, neurophysiological studies, cerebrospinal fluid analysis, nerve biopsy (in selected patients with suspected lymphomatous infiltration) and neuroimaging techniques (magnetic resonance neurography and nerve ultrasound) may be crucial for a proper diagnostic workup.
© 2018 Peripheral Nerve Society.

Entities:  

Keywords:  Waldenström's macroglobulinemia; chemotherapy; lymphoma; neurolymphomatosis; neuropathy

Mesh:

Substances:

Year:  2019        PMID: 30556258     DOI: 10.1111/jns.12295

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  9 in total

Review 1.  Update on therapy of chronic immune-mediated neuropathies.

Authors:  Chiara Briani; Dario Cocito; Marta Campagnolo; Pietro Emiliano Doneddu; Eduardo Nobile-Orazio
Journal:  Neurol Sci       Date:  2021-01-16       Impact factor: 3.307

2.  Diffuse large B-cell lymphoma relapse presenting as extensive neurolymphomatosis.

Authors:  Pankaj Nepal; Prem P Batchala; Patrice K Rehm; Camilo E Fadul
Journal:  Neuroradiol J       Date:  2020-05-13

3.  CANOMAD unmasked by COVID-19 in a man with Waldenström's macroglobulinaemia.

Authors:  Hamish D Morrison; Jonathan Cleaver; Natasha Lander; Philippa Lowden; Kate Hale; Kanchan Sharma; James Stevens
Journal:  EJHaem       Date:  2021-08-12

4.  The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG Antibodies.

Authors:  Chiara Briani; Andrea Visentin; Francesca Castellani; Mario Cacciavillani; Livio Trentin
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2022-05-16

5.  Secondary Neurolymphomatosis of the Radial Nerve: A Diagnostic Challenge.

Authors:  Francesca Iacobellis; Marco Di Serafino; Roberta Blasio; Luigi Barbuto; Filomena Pezzullo; Luigia Romano
Journal:  Am J Case Rep       Date:  2019-11-10

6.  Clinical and pathological findings in neurolymphomatosis: Preliminary association with gene expression profiles in sural nerves.

Authors:  Federica Cerri; Francesco Gentile; Ferdinando Clarelli; Silvia Santoro; Yuri Matteo Falzone; Giorgia Dina; Alessandro Romano; Teuta Domi; Laura Pozzi; Raffaella Fazio; Paola Podini; Melissa Sorosina; Paola Carrera; Federica Esposito; Nilo Riva; Chiara Briani; Tiziana Cavallaro; Massimo Filippi; Angelo Quattrini
Journal:  Front Oncol       Date:  2022-09-26       Impact factor: 5.738

7.  The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy.

Authors:  Francesca Castellani; Andrea Visentin; Marta Campagnolo; Alessandro Salvalaggio; Mario Cacciavillani; Cinzia Candiotto; Roberta Bertorelle; Livio Trentin; Chiara Briani
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-04-13

Review 8.  Recurrence of nasal type NK/T cell lymphoma presenting as neurolymphomatosis on 18F-FDG PET/CT: A case report and literature review.

Authors:  Qingqing Pan; Yaping Luo
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

Review 9.  From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance.

Authors:  Andrea Visentin; Stefano Pravato; Francesca Castellani; Marta Campagnolo; Francesco Angotzi; Chiara Adele Cavarretta; Alessandro Cellini; Valeria Ruocco; Alessandro Salvalaggio; Alessandra Tedeschi; Livio Trentin; Chiara Briani
Journal:  Cancers (Basel)       Date:  2022-03-18       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.